ReviewWorld journal of hepatology2016
Cirrhosis and autoimmune liver disease: Current understanding.
Review in World journal of hepatology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 1 synthesis or guideline pooled it, 70 citations in OpenAlex.
- Risk factors for recurrent autoimmune liver diseases after liver transplantation: A meta-analysis.Medicine · 2020Pooled it
- Genetic susceptibility and HLA association in autoimmune hepatitis among Yemeni patients.BMC immunology · 2026Article
- Diagnostic performance of FibroTest-ActiTest, transient elastography, and the fibrosis-4 index in patients with autoimmune hepatitis using histological reference.World journal of hepatology · 2025Article
- Immunosuppressive treatment in autoimmune decompensated cirrhosis, when to say enough: A retrospective analysis.Medicine · 2025Article
- Serum-urine metabolic integration via UPLC-QTOF/MS uncovers shared pathway biomarkers for cirrhosis diagnosis.Frontiers in medicine · 2025Article
- Long-Term Prednisone Use Increases Hepatocellular Carcinoma Risk in Autoimmune Hepatitis Cirrhosis: A Retrospective Cohort Study.Gastro hep advances · 2025Article
- Autoimmune hepatitis with confluent necrosis indicates severe liver injury but responds well to standard immunosuppressive therapy.Histology and histopathology · 2024Article
- Protein-centric omics analysis reveals circulating complements linked to non-viral liver diseases as potential therapeutic targets.Clinical and molecular hepatology · 2024Article
- Multivariate GWAS analysis reveals loci associated with liver functions in continental African populations.PloS one · 2023Article
- Article
- Histone acetylation of bile acid transporter genes plays a critical role in cirrhosis.Journal of hepatology · 2022Article
- Review
- Primary Biliary Cholangitis Overlap With Autoimmune Hepatitis? A Case Report.Journal of medical cases · 2021Article
- Translational Regulation in Hepatocellular Carcinogenesis.Drug design, development and therapy · 2021Review
- Metabolomic Signatures of Autoimmune Hepatitis in the Development of Cirrhosis.Frontiers in medicine · 2021Article
- Presence and type of decompensation affects outcomes in autoimmune hepatitis upon treatment with corticosteroids.JGH open : an open access journal of gastroenterology and hepatology · 2021Article
- Step by Step: Managing the Complications of Cirrhosis.Hepatic medicine : evidence and research · 2021Review
- Article
- Hospitalization costs and risk of mortality in adults with nonalcoholic steatohepatitis: Analysis of a French national hospital database.EClinicalMedicine · 2020Article
- Pulmonary Complications in Candidates for Liver Transplantation.Middle East journal of digestive diseases · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC) and autoimmune hepatitis (AIH) constitute the classic autoimmune liver diseases (AILDs). While AIH target the hepatocytes, in PBC and PSC the targets of the autoimmune attack are the biliary epithelial cells. Persistent liver injury, associated with chronic AILD, leads to un-resolving inflammation, cell proliferation and the deposition of extracellular matrix proteins by hepatic stellate cells and portal myofibroblasts. Liver cirrhosis, and the resultant loss of normal liver function, inevitably ensues. Patients with cirrhosis have higher risks or morbidity and mortality, and that in the decompensated phase, complications of portal hypertension and/or liver dysfunction lead to rapid deterioration. Accurate diagnosis and monitoring of cirrhosis is, therefore of upmost importance. Liver biopsy is currently the gold standard technique, but highly promising non-invasive methodology is under development. Liver transplantation (LT) is an effective therapeutic option for the management of end-stage liver disease secondary to AIH, PBC and PSC. LT is indicated for AILD patients who have progressed to end-stage chronic liver disease or developed intractable symptoms or hepatic malignancy; in addition, LT may also be indicated for patients presenting with acute liver disease due to AIH who do not respond to steroids.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.